Changes in Hong Kong stocks | Verishibo-B (09887) rose more than 3% LBL-034 breakthrough data released in the 2025 ASH Annual Meeting oral report

The Zhitong Finance App learned that Weilizhibo-B (09887) rose more than 3%. As of press release, it had risen 2.39% to HK$53.6, with a turnover of HK$55.77 million.

According to the news, Verishibo-B announced that the 67th ASH Annual Meeting will be held in Orlando, Florida, USA from December 6 to 9, 2025. LBL-034, a GPRC5D/CD3 bispecific antibody independently developed by the company to treat relapsed/refractory multiple myeloma (“RRMM”), gave an oral presentation for the first time on the first day of the conference.

The phase I/II clinical study of LBL-034 was led by Professor Lu Jin of Peking University People's Hospital and conducted at 17 centers across the country. The study confirmed that LBL-034 showed good safety and exciting anti-tumor activity in RRMM patients (including refractory subgroups with high-risk characteristics), showing the best treatment potential in its class.

According to Frost & Sullivan data, as of November 2024, LBL-034 is a CD3 T-cell engager targeting GPRC5D with the highest clinical progress in the world after Johnson & Johnson and China. In October 2024, LBL-034 was certified as an orphan drug (ODD) by the FDA to treat multiple myeloma.